scholarly journals Bovine Leukosis — Recent Developments with use of Monoclonal Antibodies and Elisa Tests

1984 ◽  
pp. 157-170 ◽  
Author(s):  
D. Portetelle ◽  
C. Bruck ◽  
M. Mammerickx ◽  
A. Burny
Keyword(s):  
Monoclonal Antibodies ◽  
Recent Developments ◽  
Bovine Leukosis

scholarly journals Characterization of Monoclonal Antibodies against Sporadic Bovine Leukosis Cell Lines.

1994 ◽  
Vol 56 (5) ◽  
pp. 827-833
Author(s):  
Toshie SHINAGAWA ◽  
Naotaka ISHIGURO ◽  
Motohiro HORIUCHI ◽  
Morikazu SHINAGAWA ◽  
Takane MATSUI
Keyword(s):  
Monoclonal Antibodies ◽  
Cell Lines ◽  
Bovine Leukosis

scholarly journals Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True

2020 ◽  
Vol 21 (21) ◽  
pp. 8192
Author(s):  
Mattia D’Agostino ◽  
Salvatore Innorcia ◽  
Mario Boccadoro ◽  
Sara Bringhen
Keyword(s):  
Multiple Myeloma ◽  
Monoclonal Antibodies ◽  
Tumor Targeting ◽  
Drug Class ◽  
Immune Cell ◽  
Standard Of Care ◽  
Preclinical Research ◽  
Drug Conjugates ◽  
Tumor Associated Antigen ◽  
Recent Developments

Immunotherapy is increasingly used in the treatment of multiple myeloma (MM). Monoclonal antibodies (mAbs) are safe and effective ways to elicit immunotherapeutic responses. In 2015, daratumumab has become the first mAb approved by the Food and Drug Administration for clinical use in MM and, in the last 5 years, a lot of clinical and preclinical research has been done to optimize the use of this drug class. Currently, mAbs have already become part of standard-of-care combinations for the treatment of relapsed/refractory MM and very soon they will also be used in the frontline setting. The success of simple mAbs (‘naked mAbs’) prompted the development of new types of molecules. Antibody–drug conjugates (ADCs) are tumor-targeting mAbs that release a cytotoxic payload into the tumor cells upon antigen binding in order to destroy them. Bispecific antibodies (BiAbs) are mAbs simultaneously targeting a tumor-associated antigen and an immune cell-associated antigen in order to redirect the immune cell cytotoxicity against the tumor cell. These different constructs produced solid preclinical data and promising clinical data in phase I/II trials. The aim of this review article is to summarize all the recent developments in the field, including data on naked mAbs, ADCs and BiAbs.

The evolution of immunoassay technology

Parasitology ◽  
1999 ◽  
Vol 117 (7) ◽  
pp. 13-27 ◽  
Author(s):  
A. RONALD ◽  
W. H. STIMSON
Keyword(s):  
Developing Countries ◽  
Monoclonal Antibodies ◽  
Molecular Biology ◽  
Patient Monitoring ◽  
Vast Array ◽  
Home Testing ◽  
Recent Developments ◽  
Antibody Conjugates

Since they were first utilized, immunoassays have witnessed phenomenal growth in the range and scope of their applications. A vast array of different labels and assay strategies has been developed to meet the requirements of sensitivity, accuracy and convenience. The development of increasingly sensitive labels and detection equipment has seen a drastic improvement in the sensitivity of immunoassay systems, allowing an ever-increasing range of analytes to be measured accurately. At the same time, simple to use, inexpensive assay systems have been developed with the necessary reliability, accuracy and sensitivity to bring immunoassay technology to much more diverse areas such as home testing, near-patient monitoring, and large screening programmes in developing countries. Recent developments in molecular biology techniques have made possible the production of fusion antibody conjugates, which can lead to further improvements in sensitivity and cost of reagents, as well as possibly revolutionizing the production of monoclonal antibodies. However, dissatisfaction with various aspects of existing immunoassay technology will necessarily lead to the continued development of this already widely diverse subject.

Monoclonal Antibodies by Genetic Engineering: Novel Reagents for in vivo Diagnosis and Therapy

1993 ◽  
Vol 8 (3) ◽  
pp. 147-150 ◽  
Author(s):  
S. Canevari ◽  
D. Furlan ◽  
A. Mossa ◽  
M. Figini
Keyword(s):  
Monoclonal Antibodies ◽  
Genetic Engineering ◽  
Antibody Fragments ◽  
Antibody Engineering ◽  
Present Review ◽  
Human Antibodies ◽  
Diagnosis And Therapy ◽  
Recent Developments ◽  
In Vivo Diagnosis

In only a few years, the technology of antibody engineering has demonstrated its power and a variety of recombinant monoclonal antibodies are now being developed. Recent developments in gene manipulation have allowed the isolation of antibodies, including human antibodies, with or without immunization, by displaying functional antibody fragments on the surface of bacteriophage particles and directly selecting with antigen. In the present review some recent achievements in these areas are highlighted.

Molecular heterogeneity and shedding of a high-molecular-mass melanoma-associated antigen identified with monoclonal antibodies.

1982 ◽  
Vol 28 (12) ◽  
pp. 2347-2350 ◽  
Author(s):  
A K Ng ◽  
P Giacomini ◽  
R Kantor ◽  
S Ferrone
Keyword(s):  
Monoclonal Antibodies ◽  
Molecular Mass ◽  
Melanoma Cells ◽  
High Molecular Mass ◽  
Molecular Profile ◽  
Molecular Heterogeneity ◽  
Recent Developments

Abstract This review briefly discusses some recent developments in the use of monoclonal antibodies to study antigens of high molecular mass associated with melanomas, including information on their molecular profile, their heterogeneity, and the effect of interferon on their shedding by melanoma cells.

Phenotypic Analysis of Neoplastic Cells from Calf, Thymic, and Intermediate Forms of Bovine Leukosis

1995 ◽  
Vol 32 (6) ◽  
pp. 683-691 ◽  
Author(s):  
M. Asahina ◽  
K. Kimura ◽  
K. Murakami ◽  
T. Ajito ◽  
D. Wu ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Flow Cytometric Analysis ◽  
Cell Lineage ◽  
Intermediate Form ◽  
Phenotypic Analysis ◽  
Neoplastic Cells ◽  
Cell Lineages ◽  
Major Histocompatibility Class Ii ◽  
Flow Cytometric ◽  
Bovine Leukosis

Immunohistochemistry and flow cytometric analysis were used with monoclonal antibodies to examine the phenotype of neoplastic cells from cattle with sporadic bovine leukosis (three cases of calf form, two cases of thymic form, and three cases of intermediate form). Three cases of calf form and two cases of intermediate form were positive for B cell lineage in immunohistologic examination and in flow cytometric analysis for B-B2+, sIgM+, and major histocompatibility class II+. Two cases of thymic form and one case of intermediate form were CD2+, CD5+, CD6+, and CD8+ in immunohistologic examination and in flow cytometric analysis. The results show that neoplastic cells develop from B and T cell lineages in sporadic bovine leukosis.

Sign in / Sign up

Export Citation Format

Share Document